Insights

Volpara Health Technologies (“Volpara”), which provides clinically validated software for the early detection of breast cancer, has been certified

NEXTSTELLIS was approved by the Therapeutic Goods Administration in November 2021.

De.mem treated approximately 550 million litres of water across 15 sites in Australia and Singapore.

We are pleased that Skip Capital and Stonepeak Partners recognise the value in Genex.

MedAdvisor has announced the purchase of GuildLink from the Pharmacy Guild of Australia. This will add 934 pharmacies.

Volpara is pleased to partner with such a large and well-respected organisation as RadNet.

Proteomics has announced the initial analysis of its endometriosis clinical validation study.

Substantial investment is required to transition the electricity system to net zero emissions. So this is good news.

Good news as this has the potential to create plant-based meat, dairy, baked-goods, noodles, and protein supplements.